Kamada’s philosophy embraces the joining of forces with industry partners. As each partner brings unique strengths and abilities into the partnership, we expect a greater whole to be created.

As a fully-integrated pharmaceutical company, we are is looking to complement our knowledge with the knowledge, skills, experience and resources of our partners.

To date Kamada’s strategic alliances include agreements with several partners, with a focus on product development, technology/distribution rights, raw materials supply.

Some examples of our Partnerships:

  • Strategic exclusive agreement with Takeda Ltd. for manufacturing, marketing and distributing of Glassia®, Kamada’s Alpha-1 Antitrypsin product in the US, Canada, Australia and New Zealand.
  • Strategic agreement with Kedrion Biopharma S.p.A ,a leading plasma-derived pharma company, for clinical development and marketing of KEDRAB, Kamada’s Rabies IgG product, in the US.
  • Collaboration with PARI, a worldwide leader in inhalation devices, in the development of an innovative nebulization drug- device combination for inhaled Alpha-1 Antitrypsin.
  • Ongoing collaboration with the Israel Ministry of Health in the manufacture of anti-snake serums for the treatment of snake bites, using our technology platform. Partnering with leading.
  • International pharmaceutical companies in exclusive marketing and distribution arrangements for the Israeli market.
  • Marketing our product portfolio globally through a network of long- term distributors.

We are constantly searching for further partnerships to enhance our portfolio global reach in new territories, to form strategic partnerships concerning our clinical pipeline, or to collaborate on projects that are close to Kamada’s core of business.